Xxneaxxeu Xxmitxx Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxneaxxeu Xxmitxx Pharmaceutical Import Records from India — 4 Products, $700.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxneaxxeu Xxmitxx — Pharmaceutical Importer Profile (2026) | 4 Products, $700.0K Trade | TransData Nexus

Xxneaxxeu Xxmitxx

Pharmaceutical Importer · United States · Corticosteroids Focus · $700.0K Total Trade · DGFT Verified

Xxneaxxeu Xxmitxx is a pharmaceutical importer based in United States with a total trade value of $700.0K across 4 products in 4 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxneaxxeu Xxmitxx sources from 2 verified Indian suppliers, with Amneal Pharmaceuticals Company (i) Private Limited accounting for 93.9% of imports.

Xxneaxxeu Xxmitxx — Import Portfolio & Supplier Network

Xxneaxxeu Xxmitxx import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxneaxxeu Xxmitxx?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Amneal Pharmaceuticals Company (i) Private Limited	$3.6M	92	93.9%
Epsilon Pharmaceuticals Private Limited	$236.3K	5	6.1%

Xxneaxxeu Xxmitxx sources from 2 verified Indian suppliers across 43 distinct formulations.

What Formulations Does Xxneaxxeu Xxmitxx Import?

Formulation	Value	Ships
Triamcinolone acetonide	$441.2K	10
Atropine sulfate ophthalmicsolution	$382.6K	9
Ursodiol capsules USP 300 MG 100	$267.2K	7
Methylprednisolone acetate	$214.8K	6
Fulvestrant injection 250 MG/5ML	$200.0K	4
Pregabalin capsules 150 MG 90	$150.0K	3
Norepinephrine bitartrateinjection	$150.0K	3
Pilocarpine hcl ophthalmicsolution	$100.0K	2
Etodolac tablets USP 400 MG 100	$100.0K	2
Ezetimibe tablets USP 10 MG 30	$100.0K	2
Bumetanide tablets USP 2 MG 500	$100.0K	2
Hydroxychloroquine	$100.0K	2
Bumetanide tablets USP 2 MG 100	$97.3K	2
Cyclophosphamide	$97.0K	2
Tadalafil tablets USP 20 MG 30	$94.9K	2

Xxneaxxeu Xxmitxx imports 43 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Methylprednisolone	Corticosteroids	$300.0K	6	1.0%	9
2	Fulvestrant	Advanced Oncology	$200.0K	4	1.4%	6
3	Cyclophosphamide	Oncology	$100.0K	2	0.5%	11
4	Hydroxychloroquine	Antimalarial & Antiparasitic	$100.0K	2	0.1%	14

Xxneaxxeu Xxmitxx imports 4 pharmaceutical products across 4 categories into United States totaling $700.0K.

Xxneaxxeu Xxmitxx — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxneaxxeu Xxmitxx is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing a diverse range of medications to meet domestic demand. While specific details about its headquarters and parent company are not publicly disclosed, Xxneaxxeu Xxmitxx's operations are integral to the supply chain, ensuring the availability of essential pharmaceutical products across the country.

In the period from 2022 to 2026, Xxneaxxeu Xxmitxx imported a total of $700,000 worth of pharmaceutical products from India, encompassing 14 shipments and 43 unique formulations across four therapeutic categories. This diverse portfolio underscores the company's commitment to providing a comprehensive range of medications to the U.S. market. The top five imported products include Methylprednisolone, Fulvestrant, Cyclophosphamide, and Hydroxychloroquine, reflecting a strategic focus on corticosteroids and oncology treatments.

2Distribution Network

While specific details about Xxneaxxeu Xxmitxx's warehouse locations and logistics capabilities are not publicly available, the company's substantial import activities suggest a well-established distribution network within the United States. The 14 shipments from India indicate a structured logistics operation capable of managing international supply chains efficiently. Given the diversity of imported formulations, it is likely that Xxneaxxeu Xxmitxx collaborates with various distribution centers and partners to ensure timely and compliant delivery of pharmaceutical products nationwide.

3Industry Role

Xxneaxxeu Xxmitxx functions primarily as a pharmaceutical importer and buyer within the U.S. supply chain. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company acts as a conduit between foreign manufacturers and the U.S. market. This role is crucial in ensuring the availability of a wide array of medications, including those not readily produced domestically, thereby enhancing the diversity and accessibility of pharmaceutical products available to U.S. consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxneaxxeu Xxmitxx

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxneaxxeu Xxmitxx's sourcing strategy exhibits a high degree of concentration, with a significant majority of imports originating from a single supplier, AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED, accounting for 93.9% of the total import value. This single-source dependency may present risks related to supply chain disruptions, such as production delays or regulatory issues affecting the supplier. However, the company's engagement with a secondary supplier, EPSILON PHARMACEUTICALS PRIVATE LIMITED, which contributed 6.1% to the total import value, indicates a strategic approach to mitigating such risks by diversifying sources to some extent. The stability of the relationship with AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED is critical, and any changes in this partnership could significantly impact Xxneaxxeu Xxmitxx's supply chain dynamics.

2Supply Chain Resilience

The resilience of Xxneaxxeu Xxmitxx's supply chain is closely tied to the stability and reliability of its primary supplier, AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED. The company's limited engagement with a secondary supplier suggests a potential vulnerability to disruptions. To enhance supply chain resilience, it would be prudent for Xxneaxxeu Xxmitxx to consider expanding its supplier base and diversifying the range of formulations sourced. Additionally, evaluating alternative shipping routes and ensuring compliance with international trade regulations can further strengthen the supply chain against unforeseen challenges.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) establishes the legal framework governing these activities, ensuring that all drugs imported into the U.S. are safe, effective, and properly labeled. For foreign manufacturers, including those in India, obtaining FDA approval is mandatory before exporting drugs to the U.S. market. This process involves registering with the FDA, listing all drugs intended for export, and ensuring compliance with Good Manufacturing Practice (GMP) standards. The FDA's stringent regulations are designed to maintain the integrity of the U.S. drug supply chain and protect public health.

2Import Licensing & GMP

Foreign drug establishments that manufacture, repack, re-label, or salvage drug products intended for import into the United States are required to register with the FDA before offering a drug for import and renew annually. These regulations also require foreign drug establishments to identify a U.S. Agent and include all known importers in their drug registration. Registrants are required to list with FDA each drug manufactured at their establishment(s) intended for commercial distribution and submit updated drug listing information to FDA twice each year, in June and December, notifying FDA if this information has changed.

Xxneaxxeu Xxmitxx — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxneaxxeu Xxmitxx's focus on importing corticosteroids and oncology treatments, such as Methylprednisolone, Fulvestrant, Cyclophosphamide, and Hydroxychloroquine, aligns with significant market demand in the United States. Corticosteroids are widely used for their anti-inflammatory and immunosuppressive properties, while oncology treatments are critical due to the high prevalence of cancer. The company's strategic selection of these therapeutic areas indicates a targeted approach to meet the needs of healthcare providers and patients, ensuring access to essential medications that may not be readily available from domestic sources.

2Sourcing Profile

Xxneaxxeu Xxmitxx's sourcing strategy emphasizes the procurement of generic drug formulations from India, leveraging the country's status as a major global supplier of affordable pharmaceuticals. The company's focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), suggests a preference for ready-to-market products that can be distributed directly to U.S. healthcare providers. India's well-established pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a reliable source for these formulations.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xxneaxxeu Xxmitxx

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Xxneaxxeu Xxmitxx, particularly if they can offer products that complement or diversify the existing portfolio. For instance, introducing generic formulations of other high-demand therapeutic areas or providing alternative suppliers for existing products could be advantageous. To identify gaps in Xxneaxxeu Xxmitxx's current sourcing, a detailed analysis of their existing product portfolio and supplier relationships is necessary. Establishing a partnership would require demonstrating compliance with FDA regulations, ensuring product quality, and aligning with the company's strategic objectives.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Xxneaxxeu Xxmitxx

What products does Xxneaxxeu Xxmitxx import from India?

Xxneaxxeu Xxmitxx imports 4 pharmaceutical products across 4 categories. Top imports: Methylprednisolone ($300.0K), Fulvestrant ($200.0K), Cyclophosphamide ($100.0K), Hydroxychloroquine ($100.0K).

Who supplies pharmaceuticals to Xxneaxxeu Xxmitxx from India?

Xxneaxxeu Xxmitxx sources from 2 verified Indian suppliers. The primary supplier is Amneal Pharmaceuticals Company (i) Private Limited (93.9% of imports, $3.6M).

What is Xxneaxxeu Xxmitxx's total pharmaceutical import value?

Xxneaxxeu Xxmitxx's total pharmaceutical import value from India is $700.0K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxneaxxeu Xxmitxx focus on?

Xxneaxxeu Xxmitxx imports across 4 categories. The largest: Corticosteroids (42.9%), Advanced Oncology (28.6%), Oncology (14.3%).

Get Full Xxneaxxeu Xxmitxx Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.